On Monday, Galapagos ADR reached a key performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 83, up from 77 the day before.
Risk Management In The Stock Market: How Much Money To Invest Now
This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of above 80 as they begin their biggest runs.
While Galapagos ADR is not near an ideal buy point right now, see if it goes on to form and break out of a proper consolidation.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at -8%.
Galapagos ADR holds the No. 180 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Harmony Biosciences and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
